Paratek Pharmaceuticals (PRTK) – FDA
-
Paratek Pharmaceuticals (PRTK) Announces Modification of BARDA Contract to Advance the Development of NUZYRA for Post-Exposure Prophylaxis and Treatment of Pulmonary Anthrax
-
Paratek Pharmaceuticals (PRTK) Announces EMA COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA for Treatment of Nontuberculous Mycobacterial Lung Disease
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to PRTK Stock Lookup